Hundreds of women with hard-to-treat ovarian cancer could benefit from a new, life-extending drug on the NHS from today – the first new addition to NHS treatment in over 20 years. The new targeted therapy – mirvetuximab soravtansine – will be offered to patients living with ovarian cancer whose disease has stopped responding to standard […]
Read More on the NHS website.